A continuum of multifactorial benefits of icosapent ethyl?
Video navigation menu
- Omega-3 FA intake and supplementation 1:20
- EPA clinical trials 2:54
- 3 pathways 4:55
- Lipid effects 4:13
- Anti-thrombotic effects 5:27
- Resolution of inflammation 6:32
This lecture by Prof. Bäck was part of the EBAC-accredited symposium "New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice" held during the ESC congress 2022.
Magnus Bäck is Professor of Cardiology in Stockholm, Sweden. He is the Director of Cardiovascular Research and Education at the Karolinska University Hospital and Head of Translational Cardiology at Karolinska Institutet.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Amarin.